News

EMA greenlights Novo’s degludec
Enlarge image

BusinessDenmarkFrance

EMA greenlights Novo’s degludec

22.10.2012 - The EMA has paved the road to EU approval for Novo Nordisk’s long-acting insulin Tresiba – set to become a competitor of Sanofi’s diabetes medicine Lantus.

On October 19, the European regulator said yes to the ultra long-acting insulin analogon Tresiba (insulin degludec) which had outcompeted Sanofi’s diabetes blockbuster Lantus (insulin glargine) in a Phase III head-to-head trial published this spring (Lancet). In the trial, the rate of nocturnal confirmed hypoglycaemia was 25% lower with degludec than with glargine.

Analysts estimated that Novo Nordisk’s diabetes medicine could hit peak sales of €2-3bn annually in the global €35bn diabetes market. The drug, which is also slated for FDA panel review in early November, could take a big slice of the cake in a growing diabetes market. According to market estimate, the market could reach US$58bn by 2018, according to Standard & Poor.

Novo Nordisk’s degludec, which is injected subcutaneously trice a week, lasts up to 40 hours, unlike the 18 to 26 hours provided by current marketed long-acting insulins such as insulin glargine and insulin detemir, which is also marketed by the Danes.  Degludec has one single amino acid deleted from the human form of insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/ema-greenlights-novos-deglutec.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF1987.7%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR187.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • 4SC1.09 EUR-43.2%
  • MERCK KGAA67.58 EUR-41.3%

No liability assumed, Date: 15.09.2014